Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 2200 Pennsylvania Avenue NW, Suite 300E Washingt ...

Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -22.58%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.34 per share when it actually produced a loss of $0.46, delivering a surprise of -35.29%.Over the last four quarte ...

Vanda Pharmaceuticals (NasdaqGM:VNDA) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Speaker4Hello and thank you for standing by. My name is Mark, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2025 Vanda Pharmaceuticals Inc. earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simp ...

Exhibit 99.1 Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results WASHINGTON – October 29, 2025 – Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2025. "This quarter reflects strong commercial execution, with total net product sales reaching $56.3 million, up 18% year-over-year, led by a 31% increase in Fanapt sales and 35% growth in prescriptions. HETLIOZ continues to deliver stable performance with ...

Accessibility StatementSkip Navigation WASHINGTON, Oct. 29, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2025. GAAP Financial Results Net loss was $22.6 million in the third quarter of 2025 compared to net loss of $5.3 million in the third quarter of 2024. Diluted net loss per share was $0.38 in the third quarter of 2025 compared to diluted net loss per share of $0.09 in the third quarter o ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is one of the stocks on Jim Cramer’s radar recently. When Cramer was asked about the stock toward the end of the lightning round, he said: “Well, look, here’s the way I feel about Vanda. This is a spec, and it’s absolutely like when I say in How to Make Money in Any Market: you can have a spec. I’m going to bless that one as your spec.” Photo by Joshua Mayo on Unsplash Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) develops and markets therapies for sleep, neurologic ...

On CNBC's “Mad Money Lightning Round,” Jim Cramer recommended buying Apollo Global Management (NYSE:APO).Apollo, on Oct. 6, announced that its managed funds agreed to acquire Eagle Creek Renewable Energy, one of the largest U.S. hydroelectric power platforms.National Fuel Gas Company (NYSE:NFG) has “consistency,” Cramer said.National Fuel Gas will release its fourth quarter and full year fiscal 2025 earnings results on Wednesday, Nov. 5, after the closing bell.When asked about Main Street Capital Corporatio ...

Accessibility StatementSkip Navigation Conference Call and Webcast to Follow Corporate Contact:Kevin MoranSenior Vice President, Chief Financial Officer and Treasurer Vanda Pharmaceuticals Inc. 202-734-3400 [email protected] Jim Golden / Jack Kelleher / Dan MooreCollected Strategies[email protected] SOURCE Vanda Pharmaceuticals Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? WASHINGTON, Oct. 22, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will relea ...

合作核心内容 - 范达制药成为 Monumental Sports & Entertainment 新竞技场项目的第二位创始合作伙伴，享有 Monumental Sports Network 演播室的独家冠名权，该演播室被正式命名为范达制药演播室 [1] - 此次合作是一项多年期综合性合作伙伴关系，品牌将与 NBA 华盛顿奇才队、NHL 华盛顿首都队和 WNBA 华盛顿神秘人队深度绑定，并广泛覆盖获奖的区域媒体平台 Monumental Sports Network [2] - 合作旨在讲述更宏大的故事、触达更广泛的受众并提升华盛顿特区社区，范达制药将通过在媒体内容和粉丝体验方面的深度整合，在塑造媒体未来方面发挥重要作用 [3] 媒体平台与演播室整合 - 作为冠名合作伙伴，范达制药的品牌将深度嵌入 Monumental Sports Network 制作的每一层内容中，包括赛前赛后节目、数字内容和长篇故事叙述 [4] - 范达制药演播室是 Monumental Sports Network 的广播中心，于2024年3月启用，拥有24台摄像机、1200平方英尺的4K LED显示屏和尖端机器人技术，代表了美国最先进的区域媒体环境之一 [3] - Monumental Sports Network 通过有线电视、流媒体和社交平台分发内容，每个赛季与数百万粉丝互动，已迅速成长为美国最具影响力和创新性的区域体育网络之一 [4] 品牌曝光与社区影响 - 除了演播室冠名，范达制药的品牌将出现在首都队、奇才队和神秘人队比赛的现场及转播中，并整合进 Monumental Sports Network 的比赛中特辑和内容 [6] - 范达制药将在每年接待300万宾客的资本一号竞技场的改造过程中及未来场馆资产上获得品牌曝光 [5][6] - 合作将持续支持反映双方共同价值观的本地节目，围绕创新社区影响力展开，旨在通过体育、媒体和共享体验促进国家首都的增长和机会 [5][6] 竞技场改造项目背景 - 此次合作宣布之际，下一代竞技场的第一阶段建设即将完成，该项目旨在彻底改变粉丝体验，重点关注尖端技术、沉浸式设计和社区影响力 [5][7] - 资本一号竞技场改造项目旨在打造一个高科技、高触感的场馆，以在未来25年内激励数百万年度访客 [7]

Accessibility StatementSkip Navigation Key features of the agreement include: WASHINGTON, Oct. 1, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has agreed on a collaborative framework with the U.S. Food and Drug Administration (FDA) for the resolution of certain disputes regarding HETLIOZ (tasimelteon) and tradipitant. About Vanda Pharmaceuticals Inc. Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innov ...